ArriVent Q1 net loss $17.4M; cash $317.4M; fully enrolled PACC cohort, initiated combo study

ArriVent BioPharma, Inc.

2024-Q1 EPS reported -$0.70

Cash and equivalents $317.4M as of March 31, 2024, expected to fund operations into 2026.
Net loss $17.4M for Q1 2024 vs $12.2M in Q1 2023; R&D expense $17.0M vs $10.2M.
Fully enrolled Phase 1b FURTHER trial for firmonertinib in NSCLC EGFR PACC mutations; proof-of-concept data expected in 2024.
Initiated Phase 1b combo study of firmonertinib and ICP-189 (SHP2 inhibitor) for EGFR classical mutation NSCLC.
Appointed Kristine Peterson to Board; presented preclinical AACR data showing broad activity across uncommon EGFR mutations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ArriVent BioPharma, Inc. reported first quarter ended March 31, 2024 results: net income $17.4 million.

Period: first quarter ended March 31, 2024
Net income: $17.4 million
Result: reported results

Exact text from the filing

Net loss was $17.4 million and $12.2 million for the quarters ended March 31, 2024 and 2023, respectively.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007196

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.